ArticleJournal of lipid and atherosclerosis2026
Statin Use and Site-Specific Cancer Risk: A Nationwide Cohort Study Using Korean Health Insurance Data.
Article in Journal of lipid and atherosclerosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Statins are used for cardiovascular prevention and may exert anticancer effects by modulating the mevalonate pathway and tumor microenvironment. However, population-based evidence in Koreans remains limited. This study evaluated the association between statin use and cancer risk using Korean nationwide health data. Methods: This population-based cohort study used the Korean National Health Insurance Service database. Individuals who underwent health screening in 2009-2010 were followed until 2019. Statin users referred to individuals prescribed statins for ≥6 months, whereas non-users had no statin exposure. Incident cancers were identified using International Classification of Diseases, 10th Revision, codes. Multivariable Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs). Results: Among 232,133 participants (67,064 statin users, 165,069 non-users), the incidence rate for all malignancies was 10.60 per 1,000 person-years (PY) in statin users and 10.18 per 1,000 PY in non-users. After adjusting for confounders, statin use was associated with a modest but significant reduction in overall cancer risk (aHR, 0.96; 95% confidence interval [CI], 0.93-1.00; Conclusion: In this nationwide Korean cohort, statin use was associated with a reduced risk of liver cancer but a significantly increased risk of thyroid cancer. These findings suggest organ-specific effects of statins on carcinogenesis and warrant further mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.